Exelixis and Sairopa Announce US FDA Clears Investigational New Drug Application for ADU-1805 in Patients with Advanced Solid Tumors
ALAMEDA, Calif. & ROTTERDAM, The Netherlands--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) and Sairopa B.V. (Sairopa) today announced that the companies have entered into an exclusive clinical development and option agreement for ADU-1805, a potentially best-in-class monoclonal antibody that targets SIRP?. SIRP? expressed on myeloid cells interacts with CD47 present on the surface of cancer cells and blocks the ability of macrophages to clear tumor cells via phagocytosis and inhibits tumor antigen presentation to T-cells. Blocking SIRP? has the potential to improve the immune system’s ability to attack tumors by addressing a significant immune-suppressive component of the tumor microenvironment. ADU-1805 is active against all human alleles of SIRP?, which may allow it to address a broader patient population than other SIRP?-directed therapies. ADU-1805 has also been optimized to bind preferentially to SIRP? vs. other SIRP family members, which may enhance its ability to stimulate immune cells.